Makes for some ugly reading, judging by the artice, 'surprising' accounting is an understatement: http://www.news.com.au/finance/busi...m/news-story/20b500eeefe7df2cf60489c845303372
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%